Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02012231|
Recruitment Status : Terminated
First Posted : December 16, 2013
Last Update Posted : June 3, 2016
The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered PLX8394 in patients with advanced solid tumors. An additional objective is to identify a Recommended Phase 2 (RP2D) for further evaluation in the Extension Cohorts (Phase IIa portion).
The study objective of the Extension Cohorts (PART 2 portion) is to assess the objective tumor response and the PK, PD, and safety of PLX8394 when the RP2D is used in patients with advanced BRAF-mutated cancers.
|Condition or disease||Intervention/treatment||Phase|
|Melanoma Thyroid Cancer Colorectal Cancer Non-small Cell Lung Cancer Cholangiocarcinoma Histiocytosis Hairy Cell Leukemia||Drug: PLX8394||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors|
|Study Start Date :||February 2014|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||June 2015|
Experimental: Dose Escalation
Cohort 1/Day -7 = 300 mg/day PLX8394; Cohort 1/Day 1 = 900 mg/day PLX8394
PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
- Phase 1 dose escalation: Identification of Recommended Phase 2 Dose Safety of PLX8394 [ Time Frame: 1 Year ]Physical examinations, vital signs, 12-lead electrocardiograms, adverse events, hematology, serum chemistry, and urinalysis will be used to assess safety and tolerability.
- Identification of Recommended Phase 2 dose (RP2D) [ Time Frame: 1 year ]Study drug administration is dosed continuously until clinically significant disease progression, discontinuation of study for any reason or one of the stopping criteria is met.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02012231
|United States, Arizona|
|Scottsdale, Arizona, United States, 85258|
|United States, Utah|
|Huntsman Cancer Institute|
|Salt Lake City, Utah, United States, 84112|
|United States, Washington|
|Evergreen Hematology & Oncology|
|Spokane, Washington, United States, 99218|
|Principal Investigator:||Sunil Sharma, MD||Huntsman Cancer Institute|